PMID- 25033760
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1880-4233 (Electronic)
IS  - 1340-6868 (Linking)
VI  - 23
IP  - 2
DP  - 2016 Mar
TI  - Correlation of HER2 gene status assessment by fluorescence in situ hybridization 
      between histological sections and cytological specimens of breast cancer.
PG  - 211-5
LID - 10.1007/s12282-014-0552-0 [doi]
AB  - BACKGROUND: While HER2 gene detection in cytological specimens using fluorescence 
      in situ hybridization (FISH) has been reported, the appropriate criteria for such 
      specimens remain controversial. METHODS: Fine needle aspiration (FNA) samples 
      collected from surgically resected breast cancer specimens were rinsed in a 
      cytopreservative solution containing fixative. Then, slides of the FNA samples 
      were prepared by liquid-based cytology (LBC) (ThinPrep system, Hologic) according 
      to the manufacturer's instructions, and a PathVision HER2 DNA probe kit (Abbott) 
      was used for FISH staining. The results were evaluated using an automated 
      MetaCyte imaging system (MetaSystems, Altlussheim, Germany). HER2 gene 
      amplification was scored using the HER2/chromosome enumeration probe 17 (CEP17) 
      signal count ratio as follows: amplified, >2.2; equivocal, 1.8-2.2; and 
      unamplified, <1.8. The cytology results were compared with the histology results 
      from concordant cases. RESULTS: Successful results were obtained in 98 of 100 
      cases, and results from the FNA specimens were in agreement with those from the 
      histological sections in 97 of these 98 cases (accuracy rate, 99 %; kappa, 
      0.962). CONCLUSIONS: FISH-based assessment of the HER2 gene status is consistent 
      between histological sections and cytological specimens of breast cancer.
FAU - Nishimura, Rieko
AU  - Nishimura R
AD  - Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer 
      Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan. 
      rnishimu@shikoku-cc.go.jp.
FAU - Kagawa, Akihiro
AU  - Kagawa A
AD  - Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer 
      Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan.
FAU - Tamogami, Sachiko
AU  - Tamogami S
AD  - Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer 
      Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan.
FAU - Kojima, Kenta
AU  - Kojima K
AD  - Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer 
      Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan.
FAU - Satou, Masakazu
AU  - Satou M
AD  - Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer 
      Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan.
FAU - Yamashita, Natsumi
AU  - Yamashita N
AD  - Division of Clinical Biostatistics, Section of Cancer Prevention and 
      Epidemiology, Clinical Research Center, National Hospital Organization Shikoku 
      Cancer Center, Matsuyama, Japan.
FAU - Teramoto, Norihiro
AU  - Teramoto N
AD  - Division of Clinical Biostatistics, Section of Cancer Prevention and 
      Epidemiology, Clinical Research Center, National Hospital Organization Shikoku 
      Cancer Center, Matsuyama, Japan.
AD  - Department of Pathology, National Hospital Organization Shikoku Cancer Center, 
      Matsuyama, Japan.
FAU - Aogi, Kenjiro
AU  - Aogi K
AD  - Department of Breast Oncology, National Hospital Organization Shikoku Cancer 
      Center, Matsuyama, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140718
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Biopsy, Fine-Needle
MH  - Breast Neoplasms/*diagnosis/*genetics/surgery
MH  - Female
MH  - *Gene Amplification
MH  - Germany
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Neoplasm Staging
MH  - Paraffin Embedding
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
OTO - NOTNLM
OT  - Breast cancer
OT  - Cytology
OT  - Fluorescence in situ hybridization
OT  - HER2
OT  - Histological section
EDAT- 2014/07/19 06:00
MHDA- 2016/12/15 06:00
CRDT- 2014/07/19 06:00
PHST- 2014/03/28 00:00 [received]
PHST- 2014/06/30 00:00 [accepted]
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1007/s12282-014-0552-0 [pii]
AID - 10.1007/s12282-014-0552-0 [doi]
PST - ppublish
SO  - Breast Cancer. 2016 Mar;23(2):211-5. doi: 10.1007/s12282-014-0552-0. Epub 2014 
      Jul 18.